Metastasis Flashcards Preview

Phase 2 5. People and Illness > Metastasis > Flashcards

Flashcards in Metastasis Deck (40)
Loading flashcards...
1
Q

What is metastasis?

A

Spread of tumour to- and growth at- ectopic sites, via blood, lymphatics, intra-epithelial route, or transcoelomic

2
Q

What is metastases?

A

The metastatic tumour lesion

3
Q

What is invasion?

A

growth by infiltration and destruction of surrounding tissues
i.e. growth at the primary site

4
Q

What are signs of invasion?

A

An uneven, ragged edge to the tumour.

5
Q

What is a carcinoma?

A

malignant tumour derived from the epithelial cells

6
Q

What is a sarcoma?

A

malignant tumour derived from mesenchymal cells

7
Q

What is melanoma?

A

malignant tumour derived from neural crest cells

8
Q

What is leukaemia

A

malignant tumour derived from circulating white blood cells

9
Q

What is lymphoma

A

malignant tumour derived from the lymphatic system

10
Q

What does a carcinoma have to overcome in order to metastasise?

A

The basement membranes, which act as a barrier

11
Q

Describe the metastatic cascade

A
  • local invasion
  • neovascularisation/angiogenesis
  • detatchment
  • intravasation
  • transport
  • lodgement/arrest
  • extravasation
  • growth at ectopic site
12
Q

What is the metastatic cascade?

A

process that cells need to go through in order to metastasise

13
Q

What diameter does a tumour need to exceed to develop its own blood supply?

A

> 1mm to facilitate the diffusion of nutrients and waste products

14
Q

What is intravasation?

A

The process of getting into the circulation

15
Q

What is extravasation?

A

The process of getting out of the circulation

16
Q

What is occult metastases?

A

the growing metastatic cells at an ectopic region

17
Q

What are the seven properties cells need in order to metastasise?

A

1 - reduced cell-cell adhesion
2 - altered cell-substratum adhesion
3 - increased motility
4 - increased proteolytic ability
5 - angiogenic ability
6 - ability to intravasate and extravasate
7 - ability to proliferate (locally and ectopically)

18
Q

Which of the seven properties of metastatic tumour cells are common to invasion?

A

1 - reduced cell-cell adhesion
2 - altered cell-substratum adhesion
3 - increased motility
4 - increased proteolytic ability

19
Q

Describe how reduced cell-cell adhesion can occur

A

Disrupted e-cadherin function

can be due to:

  • lack of expression
  • e-cadherin is present but has mutated to lose calcium binding site
  • the e-cadherin promoter has been switched off
  • beta cadherin, or APC mutated (molecules that interact with E-cadhein
  • mutations in transcription factors that regulate e-cadherin (snail, slug, twist)
20
Q

What is homotypic adhesion?

A

where the ligand and the receptor are the same molecule

21
Q

Describe adherens junctions

A
  • homotypic adhesion
  • E-cadherins participate
  • e-cadherin joined to linker proteins on inside of cell
  • beta-catenin is bound to the e-cadherin
  • alpha-catenin is bound to beta-catenin and actin-myposin skeleton
22
Q

What is the correlation between malignancy and e-cadherin expression?

A

The less malignant a tumour cell is histologically, the more likely it is to express e-cadherin
(most of the time, but not always)

23
Q

What are integrins?

A

Cell adhesion molecules that are integral to the plasma membrane and bind to extracellular matrix molecules

  • found in basal epithelial cells and in focal adhesions of migrating cells
24
Q

What is the role of integrins in metastasis?

A

If an endothelial tissue wants to become an endothelial tumour, it needs to switch the integrin containing junctions that fix you in place, and replace them with integrin containing junctions that facilitate movement

integrins bind to a different celladhesion molecule in a different cell type (known as heterotypic adhesion)

Specific integrin-ligand combinations have
been associated with malignant tumours. E.g.
vitronectin receptor - found in melanoma

25
Q

What are the mechanisms in which integrins are involved in metastasis?

A
  • may switch off so that the tumour cell can
    escape in the first place
  • change in integrin type so that focal
    adhesions can be formed instead of hemidesmosomes
  • adhesion to BM or blood vessel
  • act as receptors for enzymes so that the tumour cells can degrade the stroma
26
Q

What is HGF?

A

hepatocyte growth factor

HGF is a mitogen (growth factor), a motogen
(motility factor) and a morphogen with a
developmental role, e.g., in migration of limb
buds (potent in tube-like structures)

27
Q

What is HGFs role in metastasis?

A

In cell cultures - can perturb e-cadherin between epithelial cells

If there is HGF expressed in the stroma and the tumour cells happen to express a c-met, then c-met will bind and stimulate the following events:
=> activation of c-met leads to =>tyrosine phosphorylation of b-catenin in tumour epithelial cells
=> disrupted ECD-mediated adhesion

28
Q

Where is HGF roduced?

A

but produced by the stromal
cells in a tumour (cells in the tumour
microenvironment, TME).

NOT THE TUMOUR

29
Q

Why is the tumour microenvironment important?

A

can determine the behaviour of the tumour through interactions between the tumour cells and the cells in the stroma

30
Q

Name the two main families of proteases

A
  • serine proteases

- matrix metaloproteinases

31
Q

Give examples of serine proteases

A

urokinase plasminogen activator (uPA), plasmin bind to receptors on tumour cell surface (uPAR)
- heard about these in context of clotting. Can facilitate migration through the stroma

32
Q

Give examples of MMPs

A

collagenases, gelatinases, stromelysins, membrane-type (MT)-MMPs

  • soluble forms with ECM homology can bind to integrins (e.g., MMP-2 binds to avb3)
  • produced by WBCs, associated with tissue / wound repair
33
Q

What is the disadvantage of therapeutic agents targeting MMPs

A
  • create significant side effects
34
Q

Describe the role of VEGF

A

A cell in a hypoxic environment induces the expression of hypoxia inducible factor (a
transcription factor).

=> upregulation of expression of VEGF, which binds to receptors in the epithelial cells.

=> induce the endothelial cells to multiply to form tubes and to grow towards the tumour.

how you get new blood vessels growing towards the tumour.

35
Q

Describe the properties of vessels supplying a tumour

A

new blood vessels are quite leaky, allowing fibrinogen and other proteins to leak out. If
there are procoagulants in the tumour environment, these will act on fibrinogen, converting it
into fibrin. This fibrin clot is a particularly good surface for epithelial cells to migrate on.

36
Q

Describe how metastatic tumour cells are able to intravasate and extravasate

A

Behave like WBCs

Rolling and sticking is how white blood cells slow down, apply weak adhesions and then they
adhere more firmly to the vessel walls. This is a precursor for them moving into the surrounding
tissue.
One of the molecules important for this is selectin, which is expressed on white cell surface

37
Q

How are metastatic tumour cells able to proliferate?

A

tissue trophism for different tumours. I.e. preferential growth in different sites

mix of:

  • The tumour cell is the seed, but it has to fall on
    fertile soil, an appropriate tumour
    microenvironment in order to grow.
  • flow of blood supply
38
Q

What is immunoediting?

A

the immune system shapes
what the tumour is like, depending on the
different types of immune cells that get into the
tumour microenvironment,

39
Q

What are the different stages of immunoediting?

A
  • tumour cells are killed off
  • they sit in equilibrium with the surrounding
    environment
  • one of the tumour cells escapes and is able to
    grow despite the immune cells that are present
40
Q

Give an example of a treatment developed to stop the tumour cells from escaping?

A

lymphocytes with the surface antigen CTL-associated antigen-4 generally
don’t attack tumour cells. If you could somehow disable that surface antigen, then you might be
able to reawaken their ability to re-attack tumour cells

Ipilimumab is targeting that particular molecule